These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28949293)

  • 21. Naturally acquired antibodies to Plasmodium vivax blood-stage vaccine candidates (PvMSP-1₁₉ and PvMSP-3α₃₅₉₋₇₉₈ and their relationship with hematological features in malaria patients from the Brazilian Amazon.
    Mourão LC; Morais CG; Bueno LL; Jimenez MC; Soares IS; Fontes CJ; Guimarães Lacerda MV; Xavier MS; Barnwell JW; Galinski MR; Braga EM
    Microbes Infect; 2012 Aug; 14(9):730-9. PubMed ID: 22445906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
    Valderrama-Aguirre A; Quintero G; Gómez A; Castellanos A; Pérez Y; Méndez F; Arévalo-Herrera M; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):16-24. PubMed ID: 16291762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7).
    Cheng CW; Jongwutiwes S; Putaporntip C; Jackson AP
    Malar J; 2019 Jun; 18(1):197. PubMed ID: 31196098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection.
    Múfalo BC; Gentil F; Bargieri DY; Costa FT; Rodrigues MM; Soares IS
    Microbes Infect; 2008 Oct; 10(12-13):1266-73. PubMed ID: 18692152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.
    Chootong P; Panichakul T; Permmongkol C; Barnes SJ; Udomsangpetch R; Adams JH
    PLoS One; 2012; 7(4):e35769. PubMed ID: 22558221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India.
    Kale S; Yadav CP; Rao PN; Shalini S; Eapen A; Srivasatava HC; Sharma SK; Pande V; Carlton JM; Singh OP; Mallick PK
    Malar J; 2019 Dec; 18(1):425. PubMed ID: 31842894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
    Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
    Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
    Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
    Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.
    Stanisic DI; Javati S; Kiniboro B; Lin E; Jiang J; Singh B; Meyer EV; Siba P; Koepfli C; Felger I; Galinski MR; Mueller I
    PLoS Negl Trop Dis; 2013 Nov; 7(11):e2498. PubMed ID: 24244763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naturally Acquired Human Antibodies Against Reticulocyte-Binding Domains of Plasmodium vivax Proteins, PvRBP2c and PvRBP1a, Exhibit Binding-Inhibitory Activity.
    Gupta ED; Anand G; Singh H; Chaddha K; Bharti PK; Singh N; Sharma YD; Gaur D
    J Infect Dis; 2017 May; 215(10):1558-1568. PubMed ID: 28379500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.
    Bitencourt AR; Vicentin EC; Jimenez MC; Ricci R; Leite JA; Costa FT; Ferreira LC; Russell B; Nosten F; Rénia L; Galinski MR; Barnwell JW; Rodrigues MM; Soares IS
    PLoS One; 2013; 8(2):e56061. PubMed ID: 23457498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.
    Vicentin EC; Françoso KS; Rocha MV; Iourtov D; Dos Santos FL; Kubrusly FS; Sakauchi MA; Raw I; Nosten F; Rénia L; Rodrigues MM; Russell B; Soares IS
    Infect Immun; 2014 Mar; 82(3):1296-307. PubMed ID: 24379279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M.
    Oyong DA; Wilson DW; Barber BE; William T; Jiang J; Galinski MR; Fowkes FJI; Grigg MJ; Beeson JG; Anstey NM; Boyle MJ
    J Infect Dis; 2019 Nov; 220(12):1950-1961. PubMed ID: 31419296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10.
    Cheng Y; Wang B; Sattabongkot J; Lim CS; Tsuboi T; Han ET
    Parasitol Res; 2014 Jul; 113(7):2559-68. PubMed ID: 24764159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
    Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
    Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax.
    Gupta S; Singh S; Popovici J; Roesch C; Shakri AR; Guillotte-Blisnick M; Huon C; Menard D; Chitnis CE
    Sci Rep; 2018 Jul; 8(1):10511. PubMed ID: 30002416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.
    Ntumngia FB; King CL; Adams JH
    Int J Parasitol; 2012 Nov; 42(12):1055-62. PubMed ID: 23068913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions.
    Longley RJ; White MT; Takashima E; Morita M; Kanoi BN; Li Wai Suen CSN; Betuela I; Kuehn A; Sripoorote P; Franca CT; Siba P; Robinson LJ; Lacerda M; Sattabongkot J; Tsuboi T; Mueller I
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005888. PubMed ID: 28892517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon.
    de Sousa TN; Kano FS; de Brito CF; Carvalho LH
    Mem Inst Oswaldo Cruz; 2014 Aug; 109(5):608-17. PubMed ID: 25185002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.